The global Beta-Cell Replacement (Type 1 Diabetes) Market is projected...
Read More
The global Long-Acting HIV Prevention (PrEP) Market is projected to expand at an exceptional CAGR of 24.0% through 2035, driven by sustained demand for twice-yearly injectable prevention following Yeztugo’s commercial launch, growing generation of population-specific clinical evidence across diverse at-risk groups, and continued development of adherence-independent protection technology. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises Yeztugo (lenacapavir) and Apretude (cabotegravir) as the leading commercially available long-acting products, alongside the dapivirine vaginal ring and an expanding pipeline of long-acting antibody and implant-based candidates.
The market’s exceptional 24.0% CAGR reflects growing public health and clinical recognition that inconsistent daily-pill adherence has limited the effectiveness of oral PrEP, generating structured demand from sexual health and HIV prevention programs well above discretionary specialty pharmaceutical demand growth. The PURPOSE clinical trial program’s population-specific approach, evaluating cisgender women and adolescent girls in sub-Saharan Africa through PURPOSE 1 and primarily gay and bisexual men, transgender people, and gender-diverse participants through PURPOSE 2, continues to demonstrate the field’s recognition that prevention evidence must address the full diversity of at-risk populations. Coverage extending across multiple delivery technologies, duration-of-protection categories, and population-specific applications underscores the breadth of clinical and distribution infrastructure now supporting this category.
How does twice-yearly injectable demand drive the long-acting HIV prevention market?
Sexual health and HIV prevention programs continue to administer Yeztugo, delivering twice-yearly protection through its capsid inhibitor mechanism, establishing this extended dosing interval as a defining commercial differentiator for the category. As long-acting injectable adoption continues to expand, procurement associated with this extended-interval product is expected to remain a leading category through the forecast period.
What role does population-specific evidence generation growth play in market expansion?
Biopharmaceutical developers continue to generate population-specific clinical evidence through programs such as PURPOSE 1, evaluating cisgender women and adolescent girls, and PURPOSE 2, evaluating primarily gay and bisexual men, transgender people, and gender-diverse participants, sustaining structured demand from developers and prevention programs pursuing tailored evidence across the full diversity of at-risk populations.
How does adherence-independent protection adoption sustain market growth?
Prevention programs increasingly prioritize long-acting formulations designed to reduce the adherence burden associated with daily oral PrEP, sustaining structured demand above conventional daily-pill baselines. Continued technology investment in extended-duration injectable, implant, and ring-based delivery is generating demand from developers pursuing improved real-world prevention effectiveness.
What is driving demand for long-acting PrEP among adolescent and young adult populations?
Prevention programs pursuing FDA-approved injectable options extended to eligible adolescents at risk through sex continue to expand treatment access to younger populations, generating incremental demand among public health programs pursuing broader age-group coverage for HIV prevention.
How does broadly neutralizing antibody-based prevention demand sustain the market?
Biopharmaceutical developers continue to advance long-acting broadly neutralizing antibody candidates as an emerging prevention modality alongside established antiretroviral-based injectable and ring technologies, sustaining structured demand from developers pursuing this differentiated immunological prevention approach.
Which long-acting HIV prevention market segments are growing fastest?
The fastest-growing segments include twice-yearly and longer-duration injectable formats, population-specific evidence generation for transgender and gender-diverse populations, broadly neutralizing antibody-based prevention, and community-based and decentralized prevention service delivery models.
Key Players
Gilead Sciences, Inc., ViiV Healthcare Limited (GSK plc), International Partnership for Microbicides, Merck & Co., Inc., Vir Biotechnology, Inc., Population Council, UNAIDS
The Long-Acting HIV Prevention (PrEP) Market’s exceptional 24.0% CAGR outlook through 2035 is anchored in sustained twice-yearly injectable demand, growing population-specific evidence generation activity, and continued adherence-independent protection adoption. Sustained commercial and public health investment from organizations including Gilead Sciences, Inc., ViiV Healthcare Limited (GSK plc), and International Partnership for Microbicides confirms the Long-Acting HIV Prevention (PrEP) Market will sustain exceptional growth through 2035.
Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.
The global Beta-Cell Replacement (Type 1 Diabetes) Market is projected...
Read MoreThe global iPSC-Derived Neuron Replacement Therapy Market is projected to...
Read MoreThe global CAR-T for Autoimmune Disease Market is projected to...
Read More